Immupharma PLC FDA GRANTS IMMUPHARMA AMENDED SPA (5274K)

TIDMIMM

RNS Number : 5274K

Immupharma PLC

31 July 2013

FOR IMMEDIATE RELEASE 31 JULY 2013

ImmuPharma PLC

FDA GRANTS IMMUPHARMA AMENDED SPA FOR LUPUZOR PHASE III;

COMPANY PROGRESSES DEVELOPMENT ACTIVITIES

ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is delighted to announce that following its discussions with the FDA (the US Food & Drug Administraton), it has been granted an updated SPA (Special Protocol Assessment) for Lupuzor.

Under the new SPA, the necessary number of patients for the phase III programme has been reduced to 2 studies with 200 patients each. This number is lower compared to other drugs in clinical trials for lupus and underpins the significant efficacy shown by Lupuzor. Furthermore, the design of the phase III study is similar to that of the ImmuPharma phase IIb study.

ImmuPharma is now completing the manufacturing of the phase III drug supplies as well as the CMC (chemistry manufacturing and controls) section proving appropriate stability of the drug product.

Commenting on the announcement, Dr Robert Zimmer, President & Chief Scientific Officer of ImmuPharma, said: "The amended SPA is a tremendous success and validation of our development efforts and the reduced number of patients, due to the unrivalled efficacy that Lupuzor has shown in phase IIb means that the cost of the phase III trial will also be substantially lower. The phase III programme has a similar design to our phase IIb study which demonstrated substantial efficacy compared to other drugs in Lupus clinical trials."

For further information please see the Group's web site, www.immupharma.org, or contact:

 
 ImmuPharma PLC 
 Dimitri Dimitriou, Chief Executive     +44 20 7152 
  Officer                                4080 
 Robert Zimmer, President & Chief       +33 389 66 13 
  Scientific Officer                     22 
 
                                        +44 20 7152 
 Richard Warr, Chairman                  4080 
 Lisa Baderoon, Head of Investor        +44 7721 413 
  Relations                              496 
 
                                        +44 20 7886 
 Panmure Gordon & Co                     2955 
 Hugh Morgan, Fred Walsh, Grishma 
  Patel (Corporate Finance) 
  Hannah Woodley (Corporate Broking)

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, Lupuzor(TM) a potential blockbuster drug for Lupus, a chronic autoimmune disease has received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. Most recent news confirmed a five year GBP50m funding facility from Darwin Strategic and the establishment of a Scientific Advisory Board to provide scientific advice and support for Lupuzor's pivotal phase III programme. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

STRKMGFNVGNGFZM

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024